Cadrenal Therapeutics launches formal strategic review, retains Tungsten Advisors to maximize value

Cadrenal Therapeutics, Inc.

Cadrenal authorized a formal strategic process to evaluate licensing/sale of assets, partnerships, or business combinations; no timetable or assurance of a transaction.
Cadrenal engaged Tungsten Advisors as exclusive strategic financial advisor and cited strong interest from potential strategic partners.
Pipeline includes CAD-1005, tecarfarin, frunexian, and CAD-2000; CAD-1005 gained FDA alignment on a Phase 3 pathway for heparin-induced thrombocytopenia.
CAD-1005 has FDA Orphan Drug and Fast Track designations and EMA orphan drug status; tecarfarin is Phase 3-ready; frunexian is a Factor XIa inhibitor.
CEO Quang X. Pham said the pipeline has reached clinical and regulatory maturity, citing FDA alignment on CAD-1005's Phase 3 development pathway.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.